Viral Vector And Plasmid DNA Manufacturing Market To Reach $19.5 Billion By 2030


 

Viral Vector And Plasmid DNA Manufacturing Market Growth & Trends

The global viral vector and plasmid DNA manufacturing market size is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030, according to a new report by Grand View Research, Inc. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors.

With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.

Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.

Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market

Viral Vector And Plasmid DNA Manufacturing Market Report Highlights

  • Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20.0% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
  • Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
  • Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
  • Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
  • In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
  • North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement

 

Viral Vector and Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented the global viral vector and plasmid DNA manufacturing market based on the vector type, workflow, application, end-use, disease, and region:

Viral Vector and Plasmid DNA Manufacturing Vector Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Adenovirus
  • Retrovirus
  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Plasmids
  • Others

Viral Vector and Plasmid DNA Manufacturing Workflow Outlook (Revenue, USD Billion, 2018 - 2030)

  • Upstream Manufacturing
    • Vector Amplification & Expansion
    • Vector Recovery/Harvesting
  • Downstream Manufacturing
    • Purification
    • Fill Finish

Viral Vector and Plasmid DNA Manufacturing Application Outlook (Revenue, USD Billion, 2018 - 2030)

  • Antisense & RNAi Therapy
  • Gene Therapy
  • Cell Therapy
  • Vaccinology
  • Research Applications

Viral Vector and Plasmid DNA Manufacturing End-use Outlook (Revenue, USD Billion, 2018 - 2030)

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Viral Vector and Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Billion, 2018 - 2030)

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

Viral Vector and Plasmid DNA Manufacturing Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

List of Key Players in the Viral Vector and Plasmid DNA Manufacturing Market

  • Merck KGaA
  • Lonza
  • FUJIFILM Diosynth Biotechnologies
  • Thermo Fisher Scientific
  • Cobra Biologics
  • Catalent Inc.
  • Wuxi Biologics
  • Takara Bio Inc.
  • Waisman Biomanufacturing
  • Genezen laboratories
  • Batavia Biosciences
  • Miltenyi Biotec GmbH
  • SIRION Biotech GmbH
  • Virovek Incorporation
  • BioNTech IMFS GmbH
  • Audentes Therapeutics
  • BioMarin Pharmaceutical
  • RegenxBio, Inc.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/viral-vector-manufacturing-market

Comments

Post a Comment

Popular posts from this blog

Virtual Clinical Trials Market Size Reaches USD 12.9 Billion By 2030

Image
  The global  virtual clinical trials market  size is expected to reach USD 12.9 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2022 to 2030. The COVID-19 pandemic has significantly impacted the market. The growing need for patient diversity clubbed with enhanced data collection in clinical trials is boosting the market growth. There has been a rise in the R&D of new drugs and vaccines that has increased the volume and complexity of clinical trials. Virtual clinical trials eliminate challenges posed by traditional clinical trials for example delays in patient recruitment and time-consuming procedures. Also, studies have revealed that around 75.0% of people favored a mobile trial over traditional ones and 80.0% of patients are more likely to participate in a clinical trial that uses mobile technology. The market is recovering at a significant pace after the pandemic as it offers various benefits to pati
Read more

Industrial Refrigeration Systems Market Size, Share & Trends Report, 2030

Image
  Industrial Refrigeration Systems Market Growth & Trends The global  industrial refrigeration systems market  size is anticipated to reach USD 27.66 billion by 2030, registering a CAGR of 4.4% from 2023 to 2030, according to a new report published by Grand View Research, Inc. The demand for industrial refrigeration is increasing due to the fast-moving consumer goods and retail food which needs efficient storage for perishable edible items. Governments are taking initiatives to support and strengthen the cold chain infrastructure and shifting towards eco-friendly refrigeration systems. Global warming and climate change have alarmed nations to take the necessary step to curb the crisis. As a result, industrial refrigeration system manufacturing companies have expressed concerns regarding the potential of global warming and ozone depletion of their refrigerants. As a result, companies are focusing on technologies to offer improved cost-effectiveness, lesser toxic refrigerants, lower
Read more

U.S. Virtual Visits Market Size To Reach USD 105.5Bn By 2030

Image
  U.S. Virtual Visits Market Growth & Trends The  U.S. virtual visits market  size is expected to reach USD 105.5 billion by 2030, expanding at a CAGR of 29.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increasing demand for telehealth and teleconsultation and introduction of new and advanced technologies has positively impacted the growth of the market in the U.S. Increasing penetration of smartphones and assisted technologies has also been a key factor for the fast growth of the market. In the service segment, cold and flu management had the largest market share in 2022. The major factor behind the growth of the market is the growing demand for teleconsultations for patients for treatment of common conditions like cold and flu to reduce the chances of contracting additional illnesses due to hospital visits. The availability of specialists through telehealth and teleconsultations, even in remote areas has brought about a revolution in the virtual
Read more